Friday, May 3, 2019 Daily Archives

Automating Workflow Solutions, Not Instruments: Engineering Validated Processes for Biologics Screening

by

This webcast features: Brian Bordeau, Business Development, Global Advanced Workflows and Engineered Solutions, FortéBio Automation can be a lifeline for scientists working in the discovery and development of biologics. The prospects for increasing sample throughput, reducing operator time, and streamlining data audit trails are alluring. However, at the same time, introducing automation can be a frightening and confusing project, with efforts often falling short of expectations for lack of bigger picture thinking. The Advanced Workflow Engineering Solutions (AWES) team at…

May 3, 2019

China Biopharma Opportunities

by

This webcast features: Michael Frizberg, President, CMAB – Switzerland and Hong Kong and Eric Langer, Principal, BioPlan Associates China aspires to become one of if not the leading country contributor to the global pharmaceutical and biopharmaceutical industry by 2030. Large companies in this sector—both international firms expanding their own footprint within China and indigenous Chinese firms establishing both their internal and their global footprints—have witnessed double-digit growth for much of the past five to seven years. The global pharmaceutical and…

May 3, 2019

Fujifilm CDMO expands further in UK with BioCampus

by

Fujifilm Diosynth Biotechnologies (FDB) will construct a ‘BioCampus’ at its site in Northeast England at a cost of £12.6 million ($16.4 million) The contract development and manufacturing organization (CDMO) has announced plans to build a 42,000 square-foot expansion, set to house 250 staff members and create a further 50 jobs, at a cost of £12.6 million ($16.4 million). “The BioCampus is going to be constructed to transform the Billingham, UK site by building a state of the art office block…

May 3, 2019

Breathing space: Inhalable biologics interest prompts Intertek expansion

by

Interest in inhaled biologics is increasing says Intertek, which has announced plans to expand its testing facility in Melbourn, near Cambridge. Intertek will double capacity with a new 20,000 square-foot lab kitted out with technologies use to assess inhaled and nasal formulations of large molecule drugs. It also plans to hire 100 employees over the next four years. “As companies are increasingly looking at biologics for non-invasive delivery platforms like inhaled and nasal, there is expected to be an increased…

May 3, 2019

FDA pledges to support cell and gene therapy manufacturing innovation

by

Manufacturers aiming to follow Yescarta and Kymriah to market can count on FDA support after the agency said it will help cell and gene therapy firms adopt better production methods. A US Food and Drug Administration (FDA) spokesman told Bioprocess Insider the agency’s emerging technology team has been tasked with working with cell and gene therapy firms to “identify innovative approaches for efficient product manufacturing.†The move is part of a wider FDA effort to support modernization of drug manufacturing…

May 3, 2019

Repligen to buy analytics firm C Technologies for $240m

by

Repligen Corporation will expand its bioprocessing services into the process analytics space through the acquisition of C Technologies. The deal, set to close in the next few weeks, sees Repligen add Bridgewater, New Jersey-based spectroscopy firm C Technologies to its bioprocess services. The $240 million (€214 million) deal is comprised of $192 million in cash plus $48 million in Repligen common stock. Repligen has focused over the last few years on broadening out its bioprocess portfolio. While it still boasts…

May 3, 2019